| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
1 GeneCare (previously AGENE) Research Institute, Kanagawa, Japan; and 2 Department of Cellular and Molecular Biology, Division of Integrated Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Epstein-Barr virus (EBV) is closely associated with the generation of various tumors, including Burkitts lymphoma. Human resting B cells from peripheral blood are easily transformed by EBV to actively proliferating B-lymphoblastoid cell lines (LCLs). These LCLs with normal diploid karyotypes have been believed to be "immortal", without becoming tumorigenic. A series of recent studies, however, indicate that this initial, simple concept needs extensive reconsideration. Most LCLs from normal individuals are mortal because their telomeres shorten. Some LCLs are truly immortalized by developing strong telomerase activity and aneuploidy, accompanied by various other changes: down-regulation of p16/Rb; mutation of the p53 gene; modulation of apoptosis; and sensitivity to various chemical agents. Some post-immortal LCLs additionally develop the ability to form colonies in agarose and even become tumorigenic by developing the ability to grow in nude mice. The genetic background of LCLs markedly affects the frequency of immortalization. In summary, changes of B cells after infection by EBV are roughly divided into two steps: (a) transformation of B cells into LCLs caused by EBV proteins; and (b) immortalization and tumorigenesis of LCLs mainly regulated by the factors of host cells in cooperation with EBV proteins. The new concept as reviewed here is essential for the future study of tumorigenesis by EBV.
This article has been cited by other articles:
![]() |
A. R. Davis and I. S. Kohane Expression differences by continent of origin point to the immortalization process Hum. Mol. Genet., October 15, 2009; 18(20): 3864 - 3875. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Terrin, J. Dal Col, E. Rampazzo, P. Zancai, M. Pedrotti, G. Ammirabile, S. Bergamin, S. Rizzo, R. Dolcetti, and A. De Rossi Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B Lymphocytes J. Virol., October 15, 2008; 82(20): 10175 - 10187. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Le Clorennec, T.-S. Ouk, I. Youlyouz-Marfak, S. Panteix, C.-C. Martin, J. Rastelli, E. Adriaenssens, U. Zimber-Strobl, J. Coll, J. Feuillard, et al. Molecular Basis of Cytotoxicity of Epstein-Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) in EBV Latency III B Cells: LMP1 Induces Type II Ligand-Independent Autoactivation of CD95/Fas with Caspase 8-Mediated Apoptosis J. Virol., July 1, 2008; 82(13): 6721 - 6733. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bellon and C. Nicot Regulation of Telomerase and Telomeres: Human Tumor Viruses Take Control J Natl Cancer Inst, January 16, 2008; 100(2): 98 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lee and B. Sugden A Membrane Leucine Heptad Contributes to Trafficking, Signaling, and Transformation by Latent Membrane Protein 1 J. Virol., September 1, 2007; 81(17): 9121 - 9130. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dong, Y. Masaki, T. Takegami, T. Kawanami, K. Itoh, Z.-X. Jin, C.-R. Huang, X.-P. Tong, T. Fukushima, M. Tanaka, et al. Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen Int. Immunol., March 1, 2007; 19(3): 331 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Innes, A. N. Heinloth, K. G. Flores, S. O. Sieber, P. B. Deming, P. R. Bushel, W. K. Kaufmann, and R. S. Paules ATM Requirement in Gene Expression Responses to Ionizing Radiation in Human Lymphoblasts and Fibroblasts Mol. Cancer Res., March 1, 2006; 4(3): 197 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Agrawal, R. Pilarski, and C. Eng Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN Hum. Mol. Genet., August 15, 2005; 14(16): 2459 - 2468. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Tomso, A. Inga, D. Menendez, G. S. Pittman, M. R. Campbell, F. Storici, D. A. Bell, and M. A. Resnick Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation PNAS, May 3, 2005; 102(18): 6431 - 6436. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |